Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Income from Continuing Operations (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Income from Continuing Operations for 7 consecutive years, with 1006000.0 as the latest value for Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 10.82% year-over-year to 1006000.0; the TTM value through Sep 2025 reached 3633000.0, up 38.68%, while the annual FY2024 figure was 3628000.0, 71.99% up from the prior year.
  • Income from Continuing Operations hit 1006000.0 in Q3 2025 for Cyclerion Therapeutics, up from 1672000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 502000.0 in Q4 2024 and bottomed at 16176000.0 in Q2 2021.
  • Average Income from Continuing Operations over 5 years is 5857736.84, with a median of 3275000.0 recorded in 2023.
  • Year-over-year, Income from Continuing Operations tumbled 33.13% in 2023 and then skyrocketed 127.97% in 2024.
  • Cyclerion Therapeutics' Income from Continuing Operations stood at 14338000.0 in 2021, then surged by 68.93% to 4455000.0 in 2022, then surged by 59.71% to 1795000.0 in 2023, then surged by 127.97% to 502000.0 in 2024, then tumbled by 300.4% to 1006000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 1006000.0, 1672000.0, and 1457000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.